Literature DB >> 25007953

Optimal glycated albumin cutoff value to diagnose diabetes in Korean adults: a retrospective study based on the oral glucose tolerance test.

You-Cheol Hwang1, Chang Hee Jung2, Hong-Yup Ahn3, Won Seon Jeon4, Sang-Man Jin5, Jeong-Taek Woo1, Bong Soo Cha6, Jae Hyeon Kim5, Cheol-Young Park7, Byung-Wan Lee6.   

Abstract

INTRODUCTION: Glycated albumin (GA) reflects short-term status of glycemic control. We suggest a GA cut-off value to diagnose pre-diabetes and diabetes in Korean adults. In addition, we compared the performance of GA for the diagnosis of diabetes with that of glycated hemoglobin (A1c).
MATERIALS AND METHODS: A total of 852 subjects (498 males, 354 females) aged 20 to 83years (mean: 52.5years) were enrolled. A 75-g oral glucose tolerance test (OGTT) was performed and A1c and GA were measured.
RESULTS: In these enrolled subjects, 88% have glucose intolerance status (pre-diabetes or diabetes). The GA concentrations corresponding to fasting plasma glucose (FPG) of 7.0mmol/l, 2-h plasma glucose during OGTT (PPG2)≥11.1mmol/l, and A1c≥6.5% were 14.6%, 13.7%, and 14.7%, respectively. A meta-analysis of three GA cutoffs revealed a GA cutoff for diabetes of 14.3%. When A1c is used in combination with FPG, the sensitivity and specificity for the diagnosis of OGTT-based diabetes were 72.16% (95% CI: 66.6-72.2) and 96.4% (95% CI: 94.4-97.7), respectively. With the newly developed GA cutoff of 14.3%, GA combined with FPG resulted in a sensitivity and specificity of 77.5% (95% CI: 72.17-82.0) and 89.9% (95% CI: 87.1-92.2), respectively.
CONCLUSIONS: A GA cutoff of >14.3% is optimal for the diagnosis of diabetes in Korean adults. The measurement of FPG and GA may detect diabetes earlier than the measurement of FPG and A1c.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes; Diagnosis; Glycated albumin; Glycated hemoglobin; Oral glucose tolerance test

Mesh:

Substances:

Year:  2014        PMID: 25007953     DOI: 10.1016/j.cca.2014.06.027

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Establishment of Community-Based Reference Intervals for Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol.

Authors:  Elizabeth Selvin; Bethany Warren; Xintong He; David B Sacks; Amy K Saenger
Journal:  Clin Chem       Date:  2018-02-07       Impact factor: 8.327

2.  Glycated Albumin for the Diagnosis of Diabetes in US Adults.

Authors:  Michael Fang; Natalie Daya; Josef Coresh; Robert H Christenson; Elizabeth Selvin
Journal:  Clin Chem       Date:  2022-03-04       Impact factor: 8.327

Review 3.  Review of methods for detecting glycemic disorders.

Authors:  Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert
Journal:  Diabetes Res Clin Pract       Date:  2020-06-01       Impact factor: 5.602

4.  Glycated albumin and the risk of micro- and macrovascular complications in subjects with type 1 diabetes.

Authors:  Hye-jin Yoon; Yong-ho Lee; So Ra Kim; Tyler Hyungtaek Rim; Eun Young Lee; Eun Seok Kang; Bong-soo Cha; Hyun Chul Lee; Byung-wan Lee
Journal:  Cardiovasc Diabetol       Date:  2015-05-15       Impact factor: 9.951

5.  Using Glycated Albumin and Stimulated C-Peptide to Define Partial Remission in Type 1 Diabetes.

Authors:  Mei Shi; Xiaolin Ji; Yuting Xie; Ting Zhong; Rong Tang; Li Fan; Xia Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

6.  Glycated Albumin Predicts Long-term Survival in Patients Undergoing Hemodialysis.

Authors:  Chien-Lin Lu; Wen-Ya Ma; Yuh-Feng Lin; Jia-Fwu Shyu; Yuan-Hung Wang; Yueh-Min Liu; Chia-Chao Wu; Kuo-Cheng Lu
Journal:  Int J Med Sci       Date:  2016-05-10       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.